Figures computed from official regulatory filings — .
Analysttarget 15.5 USD (+489%) · consensus 4.67/5 · 5 buy · 1 hold · 0 sell
Ownershipinsiders 10.17% · institutions 86.75% · short 3.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for OnKure Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
38 buys21 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Leverone Jason A. | Sell | $898.2 | SEC |
| Saccomano Nicholas A | Sell | $258.8 | SEC |
| Agresta Samuel | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Leverone Jason A. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Agresta Samuel | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Phillips Andrew John | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Leverone Jason A. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Saccomano Nicholas A | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Manke Isaac | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Leverone Jason A. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Manke Isaac | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Saccomano Nicholas A | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Saccomano Nicholas A | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Carruthers R Michael | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Agresta Samuel | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Saccomano Nicholas A | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Saccomano Nicholas A | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Ratcliffe Liamtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Saccomano Nicholas A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Saccomano Nicholas A | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Saccomano Nicholas A | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Leverone Jason A. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Leverone Jason A. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Leverone Jason A. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Saccomano Nicholas A | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |